Results 11 to 20 of about 145,148 (243)

Plasma cell leukemia [PDF]

Blood Reviews, 2011
Plasma cell leukemia (PCL) is a rare, yet aggressive plasma cell (PC) neoplasm, variant of multiple myeloma (MM), characterized by high levels of PCs circulating in the peripheral blood. PCL can either originate de novo (primary PCL) or as a secondary leukemic transformation of MM (secondary PCL). Presenting signs and symptoms are similar to those seen
Flavio, Albarracin, Rafael, Fonseca
openaire   +2 more sources

Plasma cell leukemia

Haematologica, 2010
Moria A. Gertz, Francis K. Buadi
doaj   +3 more sources

Pleomorphic plasma cell leukemia [PDF]

Blood, 2015
![Figure][1] This peripheral blood smear is from a 72-year-old woman, taken several hours before she died of recurrent plasma cell myeloma and newly developed secondary plasma cell leukemia.
Huifei, Liu, Xiaoping, Sun
openaire   +2 more sources

Plasma cell leukemia: Clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases

Hematology/Oncology and Stem Cell Therapy, 2015
Plasma cell leukemia (PCL) is a rare hematologic malignancy with very poor outcome. It is defined by the presence of >2 × 109/L plasma cells or >20%s plasmacytosis of the differential white cell count in the peripheral blood.
Nahlah Alghasham, Randa Alnounou, Hazzaa Alzahrani, Fahad Alsharif   +3 more
doaj   +1 more source

Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study

Hematology, 2023
Background Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, exhibiting a more unfavorable prognosis than multiple myeloma. PCL is classified into pPCL and sPCL.
Jiaheng Guan, Jinlong Ma, Baoan Chen
doaj   +1 more source

Primary plasma cell leukemia and autologous stem cell transplantation

Haematologica, 2010
Background Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases. It has a poor prognosis compared to multiple myeloma, with a median survival of 8–12 months. The results of conventional therapy are
Mary B. Drake, Simona Iacobelli, Anja van Biezen, Curly Morris, Jane F. Apperley, Dietger Niederwieser, Bo Björkstrand, Gösta Gahrton   +7 more
doaj   +1 more source

Hairy Cell Leukemia with Marrow Reactive Plasmacytosis and Mast Cell Hyperplasia: A Case Report and Brief Review of the Literature [PDF]

Journal of Kerman University of Medical Sciences, 2023
Hairy cell leukemia (HCL) and HCL-like disorders, including HCL-variant, are disorders of heterogeneous mature lymphoid B-cells known for their hairy cell infiltration accompanied by a specific genetic profile, various clinical presentations, and, as ...
Elham Jafari, Behjat Kalantari Khandani, Melika Baghershahi   +2 more
doaj   +1 more source

B-lymphoblastic leukemia/lymphoma arising in treated plasma cell myeloma: A rare second malignancy

Human Pathology: Case Reports, 2017
Plasma cell myeloma (PCM) is a neoplasm of plasma cells, end-stage post germinal center B cells, which shows a variable clinical spectrum from asymptomatic to aggressive; the nature of the disease is generally progressive. Rarely, leukemia arises treated
D. Kurant, S.I. Fisher, W. Tang, N.S. Aguilera   +3 more
doaj   +1 more source

Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review. [PDF]

Front Oncol
Elsabah H, Ghasoub R, El Omri H, Benkhadra M, Cherif H, Taha RY.   +5 more
europepmc   +2 more sources

Plasma cell leukemia: A case series from South India with emphasis on rarer variants

Indian Journal of Medical and Paediatric Oncology, 2014
Plasma cell leukemia (PCL) is a rare and aggressive variant of plasma cell dyscrasia. They occur de novo (primary) or as a late manifestation of multiple myeloma (secondary). Patients present with anemia, thrombocytopenia, renal failure, organomegaly and
G Rajeswari, T Roshni Paul, Megha S Uppin, Shantveer G Uppin, D Raghunadha Rao, D Sree Bhushan Raju D, G Sadashindu   +6 more
doaj   +1 more source